Syntax Bio
PrivateLast Round
Series A
Jun 21, 2026
Total Funding Raised
$29.4M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Syntax Bio operates in Healthcare & Life Sciences and is based in Chicago, Illinois. Its latest recorded funding round was a Series A round in June 2026.
Syntax Bio is a synthetic biology company that programs the next generation of stem cell-derived therapies and organoids using its proprietary CRISPR-based Cellgorithm platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Syntax Bio Comparables
Compare Syntax Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GC Therapeutics | 85% | |
| bit.bio | 80% | |
| Mogrify | 79% |
For institutional investors. Book with your work email.
Syntax Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 21, 2026 | ||||
| Series A | Sep 17, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Syntax Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LongGame Ventures | Series A |
| DCVC Bio | Series A |
| Mansueto Office | Series A |
| EGB Capital | Series A |
| Mayo Clinic Ventures | Series A |
| Draper Associates | Series A |
| Astellas Venture Management | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 15, 2026
Grew 31% QoQ from 13 to 17 employees.
- Jul 23, 2026
Grew 21% QoQ, from 14 to 17 employees.
For institutional investors. Book with your work email.
Syntax Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Syntax Bio's valuation, stock price, and market status.
Is Syntax Bio a public or private company?
Syntax Bio is a private company.
What is the current stock price of Syntax Bio?
Syntax Bio is a private company, so its shares have no public market price. Caplight tracks Syntax Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Syntax Bio worth (valuation)?
Valuation information for Syntax Bio is not publicly available.
Can I buy Syntax Bio stock?
Syntax Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Syntax Bio's last funding round?
Syntax Bio's most recent funding round was Series A on June 21, 2026.
Who are the main investors in Syntax Bio?
Key investors in Syntax Bio include Astellas Venture Management, Illumina Ventures.
Will Syntax Bio IPO soon?
No public IPO plans have been announced for Syntax Bio.
How can I track Syntax Bio secondary market activity?
Caplight tracks bids, offers, and trades in Syntax Bio's shares on secondary markets.